Difference between revisions of "MOC31"
Jump to navigation
Jump to search
(create) |
|||
| (3 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
'''MOC31''' is an [[immunostain]]. | '''MOC31''' is an [[immunostain]]. The antibody is directed against the epithelial cell adhesion molecule (Ep-CAM, TACSTD1).<ref name=pmid19391212/> | ||
==Negative== | ==Negative== | ||
*[[Hepatocellular carcinoma]].<ref name=pmid10937059/> | *[[Hepatocellular carcinoma]].<ref name=pmid10937059>{{Cite journal | last1 = Proca | first1 = DM. | last2 = Niemann | first2 = TH. | last3 = Porcell | first3 = AI. | last4 = DeYoung | first4 = BR. | title = MOC31 immunoreactivity in primary and metastatic carcinoma of the liver. Report of findings and review of other utilized markers. | journal = Appl Immunohistochem Mol Morphol | volume = 8 | issue = 2 | pages = 120-5 | month = Jun | year = 2000 | doi = | PMID = 10937059 }}</ref> | ||
*[[Malignant mesothelioma|Malignant epithelioid mesothelioma]] - usually negative.<ref name=pmid9490276/> | |||
==Positive== | ==Positive== | ||
*[[Cholangiocarcinoma]].<ref name=pmid10937059/> | *[[Cholangiocarcinoma]].<ref name=pmid10937059/> | ||
*[[Liver metastases]].<ref name=pmid10937059/> | *[[Liver metastases]].<ref name=pmid10937059/> | ||
*[[Lung adenocarcinoma]].<ref name=pmid9490276>{{Cite journal | last1 = Ordóñez | first1 = NG. | title = Value of the MOC-31 monoclonal antibody in differentiating epithelial pleural mesothelioma from lung adenocarcinoma. | journal = Hum Pathol | volume = 29 | issue = 2 | pages = 166-9 | month = Feb | year = 1998 | doi = | PMID = 9490276 }}</ref> | |||
*[[Invasive ductal carcinoma of the breast]].<ref name=pmid19391212>{{Cite journal | last1 = Pai | first1 = RK. | last2 = West | first2 = RB. | title = MOC-31 exhibits superior reactivity compared with Ber-EP4 in invasive lobular and ductal carcinoma of the breast: a tissue microarray study. | journal = Appl Immunohistochem Mol Morphol | volume = 17 | issue = 3 | pages = 202-6 | month = May | year = 2009 | doi = | PMID = 19391212 }}</ref> | |||
*[[Invasive lobular carcinoma]].<ref name=pmid19391212/> | |||
==See also== | ==See also== | ||
*[[Immunohistochemistry]]. | *[[Immunohistochemistry]]. | ||
*[[Ber-EP4]]. | |||
==References== | ==References== | ||
Latest revision as of 16:30, 15 May 2016
MOC31 is an immunostain. The antibody is directed against the epithelial cell adhesion molecule (Ep-CAM, TACSTD1).[1]
Negative
- Hepatocellular carcinoma.[2]
- Malignant epithelioid mesothelioma - usually negative.[3]
Positive
- Cholangiocarcinoma.[2]
- Liver metastases.[2]
- Lung adenocarcinoma.[3]
- Invasive ductal carcinoma of the breast.[1]
- Invasive lobular carcinoma.[1]
See also
References
- ↑ 1.0 1.1 1.2 Pai, RK.; West, RB. (May 2009). "MOC-31 exhibits superior reactivity compared with Ber-EP4 in invasive lobular and ductal carcinoma of the breast: a tissue microarray study.". Appl Immunohistochem Mol Morphol 17 (3): 202-6. PMID 19391212.
- ↑ 2.0 2.1 2.2 Proca, DM.; Niemann, TH.; Porcell, AI.; DeYoung, BR. (Jun 2000). "MOC31 immunoreactivity in primary and metastatic carcinoma of the liver. Report of findings and review of other utilized markers.". Appl Immunohistochem Mol Morphol 8 (2): 120-5. PMID 10937059.
- ↑ 3.0 3.1 Ordóñez, NG. (Feb 1998). "Value of the MOC-31 monoclonal antibody in differentiating epithelial pleural mesothelioma from lung adenocarcinoma.". Hum Pathol 29 (2): 166-9. PMID 9490276.